echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kexing Pharmaceutical's Human Erythropoietin Injection was awarded the "Approval Notice for Supplementary Drug Application"

    Kexing Pharmaceutical's Human Erythropoietin Injection was awarded the "Approval Notice for Supplementary Drug Application"

    • Last Update: 2022-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 14, Kexing Pharmaceuticals announced that it received the “Approval Notice for Supplementary Drug Application” approved and issued by the State Food and Drug Administration on February 12.


    In the treatment of "anemia caused by chemotherapy of non-myeloid malignant tumors", large-scale human erythropoietin products can significantly reduce the frequency of medication, and improve the patient's medication compliance under the premise of equal efficacy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.